Precision in Endometrial Cancer: Personalized Treatment Strategies for pMMR and dMMR Endometrial Cancer-Decoding Endometrial Cancer: The Role of Molecular Profiling

Video Transcription

Video Summary

Dr. Brian Slomovitz and Dr. John Chan discuss the evolving management of advanced or recurrent endometrial cancer, focusing on molecular classifications—proficient mismatch repair (PMMR) and deficient mismatch repair (DMMR). Endometrial cancer has become the most lethal gynecologic cancer in the U.S., with increasing incidence and mortality, especially among Black and Hispanic women, due to factors like obesity and molecular disparities. Traditional type 1/type 2 classification is outdated; molecular profiling (e.g., TP53 mutations, HER2 status, MSI) better guides treatment. Recent paradigm shifts include the use of immune checkpoint inhibitors (ICIs) like pembrolizumab and tyrosine kinase inhibitors (TKIs), approved for both first-line and recurrent disease, adjusted by molecular subtype. Clinical trials such as RUBY, GY018, and DOE inform personalized therapy based on tumor profiles. Emerging strategies focus on selecting therapies aligned to molecular markers and considering clinical trials, emphasizing ongoing research to refine targeted approaches and address disparities for improved patient outcomes.

Keywords

endometrial cancer

molecular classification

mismatch repair

immune checkpoint inhibitors

clinical trials

health disparities